The companies plan to combine their preclinical candidates to develop small-molecule inhibitors against multiple drug targets.
Merck announced on Jan. 6, 2020 that it is entering into a research collaboration and license agreement with Taiho Pharmaceutical and Astex Pharmaceuticals worth more than $2.5 billion.
Under the agreement, Taiho and Astex will receive an upfront payment of $50 million and will be eligible to receive $2.5 billion if all preclinical, clinical, regulatory, and sales milestones are met for the products involved in the agreement, according to a Merck press release. In exchange, Merck will obtain an exclusive global license to the company’s small-molecule inhibitor candidates and will fund research, development, and global commercialization of the products.
The companies plan to combine their preclinical candidates to develop small-molecule inhibitors against multiple drug targets, including the KRAS oncogene, a mutated oncogene present in 90% of pancreatic cancers and 20% of non-small cell lung cancers, according to Merck.
“Taiho has used its unique and proprietary drug discovery platform to generate a number of small-molecule inhibitors,” said Teruhiro Utsugi, PhD, managing director at Taiho, in a company press release. “This alliance builds on our KRAS research up to now and, together with Merck, allows us to combine our expertise to significantly accelerate the global research, development, and commercialization of a number of our mutant KRAS programs by accessing external talent and resources.”
“At Merck we continue to pursue new regimens designed to extend the benefits of highly selective therapies to more patients with cancer,” added Dr. Roger M. Perlmutter, president, Merck Research Laboratories, in the press release. “This agreement with Taiho and Astex combines our respective small-molecule assets and industry-leading expertise in cancer cell signaling to enable development of the most promising drug candidates.”
Source: Merck
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.